EF Hutton Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $853

EF Hutton analyst Michael King maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $851 to $853.

EF Hutton analyst Michael King maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $851 to $853.

Total
0
Shares
Related Posts